|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Ebola Vaccines | |||||
| Marburg Virus Disease | |||||
| Ebola Virus Disease | |||||
| Marburgvirus | |||||
| Ebolavirus | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Hemorrhagic Fever, Ebola | |||||
| Virus Diseases | |||||
| 3 | More general conditions related to this trial | ||||
| Filoviridae Infections | |||||
| Hemorrhagic Fevers, Viral | |||||
| Mononegavirales Infections | |||||
| RNA Virus Infections | |||||
| 4 | Interventions listed in this trial | ||||
| VRC-EBODNA023-00-VP | |||||
| VRC-MARDNA025-00-VP | |||||
| 5 | Sponsors listed in this trial | ||||
| National Institute of Allergy and Infectious Diseases (NIAID) | |||||